Key Points
- ANI Pharmaceuticals CEO Nikhil Lalwani sold 55,000 shares on May 11 at an average price of $77.57, totaling about $4.27 million. After the sale, he still held 349,889 shares, a 13.58% reduction in ownership.
- The company reported stronger-than-expected quarterly results, with EPS of $2.05 versus $1.28 expected and revenue of $237.46 million versus $207.63 million expected. Revenue rose 20.5% year over year, and ANI raised its FY 2026 guidance to $9.19-$9.69 EPS.
- Wall Street sentiment remains positive, with several analyst upgrades and a consensus rating of “Moderate Buy.” The average price target stands at $107.33, above the stock’s recent trading level.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Thomas Andrew Rowland sold 459 shares of the stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $79.21, for a total value of $36,357.39. Following the transaction, the senior vice president directly owned 38,271 shares of the company's stock, valued at approximately $3,031,445.91. This trade represents a 1.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Thomas Andrew Rowland also recently made the following trade(s):
- On Wednesday, March 11th, Thomas Andrew Rowland sold 4,772 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $74.91, for a total value of $357,470.52.
ANI Pharmaceuticals Price Performance
Shares of NASDAQ ANIP opened at $80.88 on Thursday. The stock has a fifty day simple moving average of $77.19 and a two-hundred day simple moving average of $80.60. ANI Pharmaceuticals, Inc. has a 1-year low of $56.71 and a 1-year high of $99.50. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of 20.48 and a beta of 0.46. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The business had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. During the same period in the prior year, the company earned $1.70 earnings per share. ANI Pharmaceuticals's revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.73 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently commented on ANIP shares. Wall Street Zen raised ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, May 9th. Guggenheim raised their price target on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a "buy" rating in a report on Friday, January 16th. Finally, Zacks Research raised ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, April 15th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $107.33.
Read Our Latest Research Report on ANI Pharmaceuticals
Institutional Trading of ANI Pharmaceuticals
A number of hedge funds and other institutional investors have recently bought and sold shares of ANIP. Arrowstreet Capital Limited Partnership bought a new stake in ANI Pharmaceuticals during the 3rd quarter worth approximately $32,992,000. Balyasny Asset Management L.P. increased its holdings in ANI Pharmaceuticals by 2,785.7% during the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company's stock worth $26,211,000 after acquiring an additional 276,233 shares during the period. Divisadero Street Capital Management LP bought a new stake in ANI Pharmaceuticals during the 3rd quarter worth approximately $21,454,000. Rubric Capital Management LP boosted its stake in ANI Pharmaceuticals by 354.7% during the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company's stock valued at $16,813,000 after buying an additional 200,998 shares during the period. Finally, UBS Group AG boosted its stake in ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company's stock valued at $54,032,000 after buying an additional 185,172 shares during the period. Institutional investors own 76.05% of the company's stock.
Key Headlines Impacting ANI Pharmaceuticals
Here are the key news stories impacting ANI Pharmaceuticals this week:
- Positive Sentiment: ANI Pharmaceuticals beat first-quarter expectations, reporting $2.05 EPS versus the $1.28 consensus and revenue of $237.46 million versus $207.63 million expected. The company also raised/affirmed FY2026 guidance at $9.19-$9.69 EPS, supporting the case for continued fundamental strength.
- Positive Sentiment: Analyst sentiment remains constructive, with upgrades from Zacks Research and Wall Street Zen and a consensus “Moderate Buy” rating plus a $107.33 target price, which can help support investor confidence.
- Neutral Sentiment: ANI Pharmaceuticals published an updated investor presentation highlighting non-GAAP metrics, which may be viewed as a routine disclosure but does not appear to materially change the near-term outlook on its own. ANI Pharmaceuticals Updates Investor Presentation, Highlights Non-GAAP Metrics
- Negative Sentiment: Several insiders sold shares, including CEO Nikhil Lalwani, who sold 55,000 shares, along with sales by directors and executives Patrick D. Walsh, Meredith Cook, Ori Gutwerg, and Thomas Andrew Rowland. Heavy insider selling can raise caution among investors, even if some transactions were pre-planned.
- Negative Sentiment: A separate report said Global Alpha dumped 229,000 ANIP shares worth about $17.9 million, adding to concerns that some large holders may be trimming exposure. Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
